Selecta Biosciences

Selecta Biosciences

Selecta Biosciences was originally founded to pioneer immune-modulating therapies, with a focus on reducing the body's immune response to biologic drugs. The company is publicly traded, with headquarters in Watertown, Massachusetts, and previously maintained research footprints. Its wealth origin traces to venture capital and public equity markets. The firm's core strategy centers on the ImmTOR platform, which uses biodegradable nanoparticles to mitigate anti-drug antibodies. This technology targets rare diseases requiring repeated enzyme replacement or gene therapies, and has been validated through partnerships with larger biopharma firms. Selecta has disclosed preclinical and clinical programs in diseases such as phenylketonuria (PKU) and gout, with collaborators including Sarepta Therapeutics (per public records, 2021). Geographic focus remains primarily on the U.S. market, with some international clinical activities. Selecta Biosciences reports limited public data on team size or total deployment. The corporate structure is a publicly traded entity rather than a family office or asset manager. Recent operational developments include restructuring efforts: in September 2023, Selecta merged with Cartesian Therapeutics in a move to acquire clinical-stage pipeline assets (per SEC filings, 2023). The structural differentiator for Selecta is its dual focus on both the ImmTOR platform delivery system and the development of specific therapeutic candidates, operating as a development-stage biotech rather than a royalty or investment vehicle. This hybrid structure aligns with typical biotech company models, not a family office.